Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Spexis AG
  6. News
  7. Summary
    POLN   CH0106213793


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Swiss Takeover Board confirms Absence of an Obligation to make a Public Takeover Offer in connection with planned Enbiotix Merger

10/15/2021 | 01:32am EST

EQS Group-Ad-hoc: Polyphor AG / Key word(s): Merger Swiss Takeover Board confirms Absence of an Obligation to make a Public Takeover Offer in connection with planned Enbiotix Merger 15-Oct-2021 / 07:30 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement.


Allschwil, Switzerland, October 15, 2021 Swiss Takeover Board confirms Absence of an Obligation to make a Public Takeover Offer in connection with planned Enbiotix Merger Polyphor AG (SIX: POLN) today announced that in connection with the proposed merger with EnBiotix, Inc. ("EnBiotix"), a request for confirmation regarding the absence of an obligation to make a public tender offer was filed with the Swiss Takeover Board on October 1, 2021, on behalf of EnBiotix. The Board of Directors of Polyphor supported this request in its opinion dated October 5, 2021 (available on Polyphor's website at www.polyphor.com/investor-relations/ corporate-governance). In its decision of October 13, 2021, the Takeover Board confirmed the absence of an obligation to make a public takeover offer. The full decision including information on the background can be found at www.takeover.ch.

Decision of the Takeover Board

In its decision of October 13, 2021 (published on www.takeover.ch), the Takeover Board has decreed the following:

1. It is hereby determined that the proposed transaction set out in the presented files does not trigger an obligation to make an offer within the meaning of art. 135 para. 1 sentence 1 of the FinMIA for EnBiotix, Inc., Wired Holding Investment Corp., Apeiron Holdings Limited, Polyphor AG, James J. Collins, Trustees of Boston University, Jeffrey D. Wagner, NAEJA Pharmaceutical, Inc., YPOP II LLC and Sanford Biosciences, LLC.

2. Polyphor AG is required to publish the opinion of its Board of Directors together with the operative part of this decision (Dispositiv) and a reference to the right of objection pursuant to art. 58 TOO.

3. This decision shall be published on the website of the Takeover Board following the publication of Polyphor AG in accordance with the second paragraph of this decision.

4. The fee payable by EnBiotix, Inc. amounts to CHF 20,000.


A qualified shareholder may file an objection against the Takeover Board's decision. The objection must be filed with the Takeover Board (Stockerstrasse 54, 8002 Zurich; fax: +41 44 283 17 40) within five trading days from the date of publication of the decision of the Takeover Board. The first trading day after the publication of the decision of the Takeover Board on the Takeover Board's website will be the first day of the filing period. The objection must contain a formal request, summary reasons and proof of the qualified participation.

For further information please contact:

For Investors:          For Media: 
Hernan Levett           Dr. Stephan Feldhaus 
Chief Financial Officer Feldhaus & Partner 
Polyphor Ltd.           +41 79 865 92 56 
+41 61 567 16 00        feldhaus@feldhaus-partner.ch 

About Polyphor Polyphor is a research-oriented Swiss biopharmaceutical company with a leading macrocyclic peptide technology platform. Polyphor is headquartered in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). www.polyphor.com .

About EnBiotix Enbiotix is a privately-held, rare disease company with an initial focus on chronic respiratory diseases. EnBiotix is headquartered in Boston, Massachussets, USA with its affiliate, EnBiotix, GmbH based in Leipzig, Germany. www.enbiotix.com.

Disclaimer This press release contains forward-looking statements which are based on current assumptions and forecasts of the Polyphor management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Polyphor's results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Polyphor disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.


End of ad hoc announcement


Language:     English 
Company:      Polyphor AG 
              Hegenheimermattweg 125 
              4123 Allschwil 
Phone:        +41 61 567 1600 
Fax:          +41 61 567 1601 
E-mail:       info@polyphor.com 
Internet:     www.polyphor.com 
ISIN:         CH0106213793 
Valor:        POLN 
Listed:       SIX Swiss Exchange 
EQS News ID:  1240950 
End of Announcement EQS Group News Service 

1240950 15-Oct-2021 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1240950&application_name=news

(END) Dow Jones Newswires

October 15, 2021 01:31 ET (05:31 GMT)

All news about SPEXIS AG
2021Polyphor Finalizes Merger With EnBiotix, to Change Name to Spexis
2021Polyphor closes merger with EnBiotix and is renamed Spexis
2021EnBiotix, Inc. completed the acquisition of Polyphor AG from Novartis Venture Funds, Va..
2021EnBiotix, Inc. Closes $11M Pre-Merger Financing
2021Polyphor To Close EnBiotix Merger Before 2021-End
2021Polyphor to inform about the financing of its merger partner EnBiotix
2021Polyphor Treats First Patient in Early-Stage Study of Inhaled Antibiotic
2021Polyphor and EnBiotix announce dosing of first patient in a first-in-human clinical tri..
2021Polyphor and Enbiotix Announces Dosing of First Patient in a First-In-Human Clinical Tr..
2021Polyphor, EnBiotix Shareholders Green-Light Merger, Name Change
More news
Sales 2020 14,3 M 15,6 M 15,6 M
Net income 2020 -44,9 M -49,3 M -49,3 M
Net cash 2020 25,1 M 27,5 M 27,5 M
P/E ratio 2020 -2,01x
Yield 2020 -
Capitalization 20,6 M 22,6 M 22,6 M
EV / Sales 2019 1 845x
EV / Sales 2020 4,63x
Nbr of Employees 52
Free-Float -
Duration : Period :
Spexis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SPEXIS AG
Short TermMid-TermLong Term
Income Statement Evolution
Managers and Directors
G÷khan Batur Chief Executive Officer
Hernan Levett Chief Financial Officer
Kuno Sommer Chairman
Frank T. Weber Chief Medical & Development Officer
Bernard Bollag Independent Director